Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Notified -
Globe Newswire4-12-2024, 14:00
ATN to Present at Sidoti Spring 2023 Small Cap Virtual 9-03-2023, 21:37